Research programme: small molecule therapeutics - HitGen/LEO Pharma

Drug Profile

Research programme: small molecule therapeutics - HitGen/LEO Pharma

Latest Information Update: 15 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator HitGen
  • Developer HitGen; LEO Pharma
  • Class Skin disorder therapies; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Skin disorders

Most Recent Events

  • 07 Aug 2017 Early research in Skin disorders in China (unspecified route)
  • 07 Aug 2017 HitGen enters into a collaboration with LEO Pharma for developing candidates for Skin disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top